Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #3
Study Details
Study Description
Brief Summary
The purpose of this study is to collect alcohol calibration data for the driving simulator.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Blood alcohol concentration (BAC) level 0.025 % Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025% |
Other: Road-tracking test
Driving with simulator program for SDLP measurement
Other: Car-following test
Driving with simulator program for DCV measurement
Other: Harsh-braking test
Driving with simulator program for BRT measurement
|
Other: BAC level 0.05 % Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05% |
Other: Road-tracking test
Driving with simulator program for SDLP measurement
Other: Car-following test
Driving with simulator program for DCV measurement
Other: Harsh-braking test
Driving with simulator program for BRT measurement
|
Other: BAC level 0.09 % Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09% |
Other: Road-tracking test
Driving with simulator program for SDLP measurement
Other: Car-following test
Driving with simulator program for DCV measurement
Other: Harsh-braking test
Driving with simulator program for BRT measurement
|
Other: BAC level 0 % Drink beverages containing non alcohol |
Other: Road-tracking test
Driving with simulator program for SDLP measurement
Other: Car-following test
Driving with simulator program for DCV measurement
Other: Harsh-braking test
Driving with simulator program for BRT measurement
|
Outcome Measures
Primary Outcome Measures
- Standard Deviation of Lateral Position (SDLP) [60 min]
Secondary Outcome Measures
- Distance Coefficient of Variation (DCV) [5 min]
- Brake Reaction Time (BRT) [5 min]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Body mass index (BMI) ≥18.5 and <25.0 kg/m^2 at screening inspection
-
No visual impairment (enable to correct the vision with eyeglasses or contact lens)
-
Receive a prior explanation on the study, able to accept its content, and capable to provide voluntary written consent for participation in this study
Exclusion Criteria:
-
History of drug and food allergy
-
Alcohol dependence, drug dependence or abnormal drunken (including past history)
-
Inappropriate for enrollment in this study was judged by principal investigator or subinvestigator
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Taisho Pharmaceutical Co., Ltd selected site | Fukuoka | Japan |
Sponsors and Collaborators
- Taisho Pharmaceutical Co., Ltd.
- Nagoya University
Investigators
- Study Director: Shigeru Okuyama, Taisho Pharmaceutical Co., Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DS-204-03
- JapicCTI-184006